2,529
Views
22
CrossRef citations to date
0
Altmetric
Special Section: A Collection of Articles on Opportunities and Challenges in Utilizing Real-World Data for Clinical Trials and Medical Product Development

Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment

, , , , , , , , , ORCID Icon, & show all
Pages 3-13 | Received 01 May 2020, Accepted 26 Jan 2021, Published online: 10 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (12)

Mark Levenson, Weili He, Li Chen, Sai Dharmarajan, Rima Izem, Zhaoling Meng, Herbert Pang & Frank Rockhold. (2023) Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development. Statistics in Biopharmaceutical Research 15:3, pages 689-696.
Read now
Freda Cooner, Ran Liao, Junjing Lin, Sophie Barthel, Yodit Seifu & Shiling Ruan. (2023) Leveraging Real-World Data in COVID-19 Response. Statistics in Biopharmaceutical Research 15:3, pages 582-595.
Read now
Mark Levenson & Weili He. (2023) Rejoinder to the Commentaries on “The Current Landscape in Biostatistics of Real-World Data and Evidence: Label Expansion”. Statistics in Biopharmaceutical Research 15:1, pages 27-28.
Read now
Lisa V. Hampson, Evgeny Degtyarev, Rui (Sammi) Tang, Jianchang Lin, Kaspar Rufibach & Cheng Zheng. (2023) Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment”. Statistics in Biopharmaceutical Research 15:1, pages 23-26.
Read now
Yukari Uemura, Tomohiro Shinozaki, Shogo Nomura & Taro Shibata. (2023) Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment”. Statistics in Biopharmaceutical Research 15:1, pages 20-22.
Read now
Weili He, Yixin Fang, Hongwei Wang & Ivan Chan. (2023) Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. Statistics in Biopharmaceutical Research 15:1, pages 57-68.
Read now
Xiang Yin, Pallavi S. Mishra-Kalyan, Rajeshwari Sridhara, Mark D. Stewart, Elizabeth A. Stuart & Ruthanna C. Davi. (2022) Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer. Journal of Biopharmaceutical Statistics 32:1, pages 204-218.
Read now
Nelson Lu, Chenguang Wang, Wei-Chen Chen, Heng Li, Changhong Song, Ram Tiwari, Yunling Xu & Lilly Q. Yue. (2022) Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources. Journal of Biopharmaceutical Statistics 32:1, pages 158-169.
Read now

Articles from other publishers (10)

Jonathan Cimino & Claude Braun. (2023) Design a Clinical Research Protocol: Influence of Real-World Setting. Healthcare 11:16, pages 2254.
Crossref
Susan Gruber, Rachael V. Phillips, Hana Lee, John Concato & Mark van der Laan. (2023) Evaluating and improving real-world evidence with Targeted Learning. BMC Medical Research Methodology 23:1.
Crossref
Stella Erdmann, Dominic Edelmann & Meinhard Kieser. (2023) Using real‐world data to predict health outcomes—The prediction design: Application and sample size planning. Biometrical Journal 65:6.
Crossref
Liang Li & Thomas Jemielita. (2023) Confounding adjustment in the analysis of augmented randomized controlled trial with hybrid control arm. Statistics in Medicine 42:16, pages 2855-2872.
Crossref
Youngsoo Lee, Ji-Hyang Lee, So Young Park, Ji-Ho Lee, Joo-Hee Kim, Hyun Jung Kim, Sang-Heon Kim, Kian Fan Chung & Woo-Jung Song. (2023) Roles of real-world evidence in severe asthma treatment: challenges and opportunities. ERJ Open Research 9:2, pages 00248-2022.
Crossref
Jixian Wang, Hongtao Zhang & Ram Tiwari. 2023. Real-World Evidence in Medical Product Development. Real-World Evidence in Medical Product Development 233 254 .
Weili He, Yixin Fang, Hongwei Wang & Charles Lee. 2023. Real-World Evidence in Medical Product Development. Real-World Evidence in Medical Product Development 3 16 .
Jing Liu, Jeffrey S. Barrett, Efthimia T. Leonardi, Lucy Lee, Satrajit Roychoudhury, Yong Chen & Panayiota Trifillis. (2022) Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives. The Journal of Clinical Pharmacology 62:S2.
Crossref
Olivier Collignon, Anja Schiel, Carl‐Fredrik Burman, Kaspar Rufibach, Martin Posch & Frank Bretz. (2022) Estimands and Complex Innovative Designs. Clinical Pharmacology & Therapeutics 112:6, pages 1183-1190.
Crossref
Julian C. Hong. (2021) Strategies to Turn Real-world Data Into Real-world Knowledge. JAMA Network Open 4:10, pages e2128045.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.